Single-agent venetoclax in multiply relapsed/refractory MM patients demonstrated an ORR of 40% among those with t(11;14), whilst BCL2:MCL1 and BCL2:BCL2L1 mRNA expression levels correlated with responses and with t(11;14) status [129]. This evidence concerns the gene BCL2 and Miyoshi myopathy.